A validation study for the utility of serum microRNA as a diagnostic and prognostic marker in patients with osteosarcoma

Yoshihiro Araki, Naofumi Asano, Norio Yamamoto, Katsuhiro Hayashi, Akihiko Takeuchi, Shinji Miwa, Kentaro Igarashi, Takashi Higuchi, A. B.E. Kensaku, Yuta Taniguchi, Hirotaka Yonezawa, Sei Morinaga, Yohei Asano, Takeshi Yoshida, Rikinari Hanayama, Juntaro Matsuzaki, Takahiro Ochiya, Akira Kawai, Hiroyuki Tsuchiya

Research output: Contribution to journalArticlepeer-review


In our previous study, osteosarcoma advanced locally, and metastasis was promoted through the secretion of large number of small extracellular vesicles, followed by suppressing osteoclastogenesis via the upregulation of microRNA (miR)‑146a‑5p. An additional 12 miRNAs in small extracellular vesicles were also detected ≥6x as frequently in high‑grade malignancy with the capacity to metastasize as in those with a low metastatic potential. However, the utility of these 13 miRNAs for determining the prognosis or diag‑ nosis of osteosarcoma has not been validated in the clinical setting. In the present study, the utility of these miRNAs as prognostic and diagnostic markers was therefore assessed. In total, 30 patients with osteosarcoma were retrospectively reviewed, and the survival rate was compared according to the serum miRNA levels in 27 patients treated with chemotherapy and surgery. In addition, to confirm diagnostic competency for osteosarcoma, the serum miRNA levels were compared with those in patients with other bone tumors (n=112) and healthy controls (n=275). The patients with osteosarcoma with high serum levels of several miRNAs (miR‑146a‑5p, miR‑1260a, miR‑487b‑3p, miR‑1260b and miR‑4758‑3p) exhibited an improved survival rate compared with those with low levels. In particular, patients with high serum levels of miR‑1260a exhibited a significantly improved overall survival rate, metas‑ tasis‑free survival rate and disease‑free survival rate compared with those with low levels. Thus, serum miR‑1260a may potentially be a prognostic marker for patients with osteosar‑ coma. Moreover, patients with osteosarcoma had higher serum miR‑1261 levels than those with benign or intermediate‑grade bone tumors and thus may be a potential therapeutic target, in addition to being useful for differentiating whether or not a bone tumor is high‑grade. A larger investigation is required to clarify the actual utility of these miRNAs in the clinical setting.

Original languageEnglish
Article number222
JournalOncology Letters
Issue number6
Publication statusPublished - 2023 Jun


  • diagnosis
  • marker
  • osteosarcoma
  • prognosis
  • serum miRNA
  • utility
  • validation

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'A validation study for the utility of serum microRNA as a diagnostic and prognostic marker in patients with osteosarcoma'. Together they form a unique fingerprint.

Cite this